Measurements of serum triiodothyronine (T3) concentrations were made in 46 patients who had thyroid ablation for thyroid cancer and who were receiving T3 three times a day as suppressive treatment. In all patients thyrotropin (TSH) suppression was confirmed by the inhibition of TSH response to thyrotropin releasing hormone (TRH). The suppressive dose of T3 varied from 40 to 100 μg/day (mean ± SD 72.39 + 13.07 μg/day). Related to body weight the dose varied from 0.95 to 1.35 μg/kg/day (mean ± SD 1.13 ± 0.13 μg/kg/day). In ten hospitalized patients serum T3 levels were measured at hourly intervals from 08:00 to 23:00. Before the first dose of T3, serum T3 levels were 153 ± 43 ng/100 ml; after T3 the levels increased promptly reaching after 4 h a peak of 264 ± 90 ng/100 ml. Afterwards T3 levels showed asimilar peak after each dose: 262 ± 77 and 266 ± 78 ng/100 ml, slightly decreasing in the intervals between the doses: 227 ± 63 and 255 ± 69 ng/100 ml. After the last peak T3 levels showed a slow decline during the night. TSH response to TRH was completely inhibited both at 08:00 and at 16:00. In 36 outpatients T3 levels were measured twice a day and T3 levels were found similar to the ones of the first group. In these patients also TSH response to TRH evaluated at 08:00 was completely inhibited. No important side effect was noted in both groups of patients.
- thyroid cancer
- thyroid hormone suppressive therapy
- Triiodothyronine levels
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism